Delcath Systems, Inc. Profile Avatar - Palmy Investing

Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery s…

Medical - Specialties
US, New York [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Delcath Systems, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of DCTH's Analysis
CIK: 872912 CUSIP: 24661P807 ISIN: US24661P8077 LEI: - UEI: -
Secondary Listings
DCTH has no secondary listings inside our databases.